科研之友
微信
新浪微博
Facebook
分享链接
摘要
This paper reports prescribing patterns for prophylaxis of chemotherapy-induced nausea and vomiting (CINV) after highly or moderately emetogenic chemotherapy (HEC or MEC) for cancer in six Asia Pacific countries. In a prospective noninterventional study, 31 sites in Australia, China, India, Singapore, South Korea, and Taiwan recorded details of CINV prophylaxis for the acute phase (first 24 h) and delayed phase (days 2-5) after single-day HEC or MEC for adult patients. Additional information on CINV prophylactic medications was collected from 6-day patient diaries. Primary antiemetic therapies were defined as corticosteroids, the 5-hydroxytryptamine-3 receptor antagonists (5HT3-RAs), and neurokinin-1 receptor antagonists (NK1-RAs). Evaluable patients in cycle 1 numbered 648 (318 [49 %] HEC and 330 [51 %] MEC) of mean (SD) age of 56 (12) years, including 58 % women. For the acute phase after HEC, overall (and country range), 96 % (91-100 %) of patients received a 5HT3-RA, 87 % (70-100 %) a corticosteroid, and 43 % (0-91 %) an NK1-RA. CINV prophylaxis for the HEC delayed phase was more variable: including 22 % (7-65 %) 5HT3-RA, 52 % (12-93 %) corticosteroid, and 46 % (0-88 %) NK1-RA. For the MEC acute phase, 97 % (87-100 %) of patients received 5HT3-RA and 86 % (73-97 %) a corticosteroid. For the MEC delayed phase, 201 patients (61 %) received a primary antiemetic, including 5HT3-RA (41 %), corticosteroid (37 %), and/or NK1-RA (4 %). The 5HT3-RAs were prescribed consistently in all countries, while prescribing of other antiemetic therapies was variable, and corticosteroids were under-prescribed for CINV prophylaxis, particularly in the delayed phase.
